Representations and Prevention of Cancers in Schools
RISCOLAIRE
RISCOLAIRE
Sponsor study identifier
observational
191
0 countries
N/A
Study Start
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2013
Actual (reported)Study Completion
November 2013
Actual (reported)The main objective is to develop an educational program and to measure the impact on social representations identified as acting in the prevention of cancer. Child should write, draw and speak about cancer signifiance to identify individual conceptions and representations of health and cancer in children aged 9 to 12 years in school.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2013
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
November 2013
Actual (reported)November 2013
Actual (reported)February 6, 2015
Actual (reported)March 4, 2015
Actual (reported)Number of cancer and health representations in children
Identification of individual cancer and health conceptions and representations in children aged 9 to 12 years in schools
60 minutes
Number of association of cancer and health representations with the ecological deprivation index
60 minutes
Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
Franck Chauvin, PhDMD
ICLN
191 participants (actual enrollment reported by the registry).
First Submitted
February 6, 2015
First Posted
March 4, 2015
Study Start
September 2012
Date type not reportedThis date has not been verified as actual or estimated.
Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Contact the study team to confirm eligibility.
Primary Completion
November 2013
Actual (reported)Study Completion
November 2013
Actual (reported)Last Updated
March 4, 2015
Record last verified: 2015-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: